Bellerophon Therapeutics Receives EC Certification for New INOpulse® Drug-Device Delivery System
January 19, 2016 08:03 ET
|
Bellerophon Therapeutics LLC
WARREN, N.J., Jan. 19, 2016 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today announced that it has received EC Certification...
Bellerophon Reports 2015 Third Quarter Operational and Financial Results
November 12, 2015 06:03 ET
|
Bellerophon Therapeutics LLC
Phase 3 trial for patients with PAH on track to start enrollment by year-end Special Protocol Assessment (SPA) issued by FDA for Phase 3 program Company plans to continue Phase 2 testing in COPD...
Bellerophon Announces Functional Respiratory Imaging Data From Company Sponsored Clinical Trial of INOpulse(R) in COPD Patients With Pulmonary Hypertension Presented Today at the European Respiratory Society (ERS) International Congress
September 30, 2015 07:03 ET
|
Bellerophon Therapeutics LLC
HAMPTON, N.J., Sept. 30, 2015 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, announced that an oral presentation of late-breaking data from...
Bellerophon Therapeutics Announces Positive Data From Interim Analysis of Phase 2 Long-Term Extension Study of INOpulse(R) for Treatment of Pulmonary Arterial Hypertension
September 24, 2015 16:30 ET
|
Bellerophon Therapeutics LLC
Conference Call/Webcast to Be Held September 25, 2015 at 9:00am ET
Interim Data Reinforces Earlier Phase 2 Data and Indicates Sustainability of Benefits for PAH Patients
FDA Issues a Special...
Bellerophon Therapeutics Announces Leadership Team Changes
September 15, 2015 08:07 ET
|
Bellerophon Therapeutics LLC
- Confirms Focus on Developing INOpulse® Nitric Oxide Therapy for Patients with Pulmonary Hypertension -
- Headcount and Costs Substantially Reduced -
HAMPTON, N.J., Sept. 15, 2015 (GLOBE...
Bellerophon to Present in Upcoming Investor Conferences
September 03, 2015 16:23 ET
|
Bellerophon Therapeutics LLC
HAMPTON, N.J., Sept. 3, 2015 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today announced that Chairman and Chief Executive Officer...
Bellerophon Reports 2015 Second Quarter Operational and Financial Results
August 13, 2015 18:33 ET
|
Bellerophon Therapeutics LLC
HAMPTON, N.J., Aug. 13, 2015 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today reported operational and financial results for the second...
Bellerophon Therapeutics Expands License Agreement With INO Therapeutics to Develop INOpulse(R) for Three Additional Cardiopulmonary Diseases
July 29, 2015 06:03 ET
|
Bellerophon Therapeutics LLC
HAMPTON, N.J., July 29, 2015 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today announced that it has expanded its license agreement with...
Bellerophon Therapeutics Announces Top-Line Results From PRESERVATION I Clinical Trial for Bioabsorbable Cardiac Matrix (BCM)
July 27, 2015 06:00 ET
|
Bellerophon Therapeutics LLC
HAMPTON, N.J., July 27, 2015 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical stage biotherapeutics company with programs focused on the treatment of cardiopulmonary and...
Bellerophon Therapeutics Announces Management and Board Additions
July 01, 2015 07:32 ET
|
Bellerophon Therapeutics LLC
HAMPTON, N.J., July 1, 2015 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today announced the appointments of Amit Agrawal as Chief...